New treatment approach shows potential in reversing lung damage caused by idiopathic pulmonary fibrosis using immune-based ...

The following is a summary of "ADORA2B promotes proliferation and migration in head and neck squamous cell carcinoma and is ...

Older adults with cancer respond just as well as younger patients to immune checkpoint inhibitors despite age-related immune ...

Removing EPO signaling in mouse liver tumors leads to tumor regression along with sensitivity to immunotherapy.

Recent studies highlight the potential pathophysiology and presentation of immune checkpoint inhibitor–associated cutaneous ...

Researchers have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people worldwide.

Older adults with cancer respond just as well as younger patients to immune checkpoint inhibitors despite age-related immune system differences, according to a study by researchers from the Johns ...

SparX Biopharma to present phase 1 clinical updates of SPX-303, a dual checkpoint bispecific antibody, during AACR 2025: Chicago Monday, April 21, 2025, 16:00 Hrs [IST] SparX Biop ...

Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people ...

Older adults with cancer respond just as well as younger patients to immune checkpoint inhibitors despite age-related immune system differences, according to a new study.